VIASKIN® Peanut (DBV712)

About DBV Technologies

DBV Technologies is a clinical-stage biopharma on a mission to develop safe, effective epicutaneous immunotherapy (EPIT) for food allergies and other immunological conditions via its proprietary VIASKIN® patch. Its key achievement is the positive Phase 3 VITESSE trial for its peanut patch (DBV712) in children aged 4-7, positioning it as a potential first-in-class EPIT treatment. The company's strategy leverages its transdermal platform to address significant unmet needs in allergy care, with a pipeline extending to milk allergy and future inflammatory diseases. Recent inclusion in major Euronext indices reflects growing market recognition of its progress.

About DBV Technologies

DBV Technologies is a clinical-stage biopharma on a mission to develop safe, effective epicutaneous immunotherapy (EPIT) for food allergies and other immunological conditions via its proprietary VIASKIN® patch. Its key achievement is the positive Phase 3 VITESSE trial for its peanut patch (DBV712) in children aged 4-7, positioning it as a potential first-in-class EPIT treatment. The company's strategy leverages its transdermal platform to address significant unmet needs in allergy care, with a pipeline extending to milk allergy and future inflammatory diseases. Recent inclusion in major Euronext indices reflects growing market recognition of its progress.

Therapeutic Areas